Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 665.

https://doi.org/10.1182/blood-2025-665

Published: 2025

Journal Articles

Uncovering practice gaps in the management of mantle cell and diffuse large B-cell lymphomas amidst advances with Bruton's tyrosine kinase inhibitors

Tisheeka Graham, Tariqa Ackbarali, Katie Kowalski, Anita Kumar, Matthew Matasar, Caron Jacobson, Kami Maddocks

Blood (2025) 146 (Supplement 1): 8106.

https://doi.org/10.1182/blood-2025-8106

Published: 2025

Journal Articles

Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial

Blood (2025) 146 (Supplement 1): 464.

https://doi.org/10.1182/blood-2025-464

Published: 2025

Journal Articles

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Blood (2025) 146 (Supplement 1): 2385.

https://doi.org/10.1182/blood-2025-2385

Published: 2025

Journal Articles

Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis

Alyssa Kassouf, Rina Welkie, Yazeed Sawalha, Audrey Sigmund, Timothy Voorhees, Yun Choi, Robert Baiocchi, Jordan Lundberg, Tracy Wiczer, Tyler Everhardt, Caitlyn Crawford, Rebecca Evers, Lindsay Rosen, Beth Christian, Kami Maddocks, David Bond

Blood (2025) 146 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2025-4526

Published: 2025

Journal Articles

Real-world treatment patterns, patient characteristics, and outcomes of cbtki-based therapies amongst a contemporary cohort of patients with R/R MCL in the United States

Kami Maddocks, Marsha Tracey, Katherine Winfree, Elyse Hall Panjic, Alan Brnabic, Dan He, Jonathon Cohen

Blood (2025) 146 (Supplement 1): 2725.

https://doi.org/10.1182/blood-2025-2725

Published: 2025

Journal Articles

Demystifying changes with upfront therapy in Mantle Cell Lymphoma: Global clinician preparedness in the aftermath of educational interventions

Carmine Deluca, Toby Eyre, Christine Ryan, Kami Maddocks, Pier Luigi Zinzani, Michael Beyer, Ben Johnson, Abigail Brugger, Jessica Massey, Andrea Corti

Blood (2025) 146 (Supplement 1): 2869.

https://doi.org/10.1182/blood-2025-2869

Published: 2025

Journal Articles

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease

Blood (2025) 146 (Supplement 1): 1935.

https://doi.org/10.1182/blood-2025-1935

Published: 2025

Journal Articles

Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder

Timothy Voorhees, Rina Welkie, Hemalatha Rao, Yazeed Sawalha, David Bond, Audrey Sigmund, Yun Choi, John Reneau, Walter Hanel, Polina Shindiapina, Jonathan Brammer, Beth Christian, Lapo Alinari, Nancy Bartlett, Kami Maddocks, Robert Baiocchi

Blood (2025) 146 (Supplement 1): 8240.

https://doi.org/10.1182/blood-2025-8240

Published: 2025

Journal Articles

Phase IB/II trial of epcoritamab plus ibrutinib in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Yazeed Sawalha, Marie Hu, Rina Welkie, Aubree Shoemaker, Yun Choi, Audrey Sigmund, Timothy Voorhees, David Bond, John Reneau, Lapo Alinari, Jonathan Brammer, Beth Christian, Robert Baiocchi, Veronika Bachanova, Kami Maddocks

Blood (2025) 146 (Supplement 1): 8239.

https://doi.org/10.1182/blood-2025-8239

Published: 2025

Journal Articles

BTKi is better: a lesson learned?

Kami Maddocks

Blood (2024) 144 (9): 926–927.

https://doi.org/10.1182/blood.2024025105

Published: 2024

Journal Articles

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Blood (2023) 142 (26): 2327–2331.

https://doi.org/10.1182/blood.2023021274

Published: 2023

Includes: Supplemental data

Journal Articles

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

Blood (2022) 139 (13): 1999–2010.

https://doi.org/10.1182/blood.2021011894

Published: 2022

Includes: Supplemental data

Journal Articles

Building on BTK inhibition in MCL

Kami Maddocks

Blood (2021) 137 (7): 861–862.

https://doi.org/10.1182/blood.2020009781

Published: 2021

Journal Articles

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Peter Martin, Nancy L. Bartlett, Kristie A. Blum, Steven Park, Kami Maddocks, Jia Ruan, LeAnn Ridling, Christopher Dittus, Zhengming Chen, Xiangao Huang, Giorgio Inghirami, Maurizio DiLiberto, Selina Chen-Kiang, John P. Leonard

Blood (2019) 133 (11): 1201–1204.

https://doi.org/10.1182/blood-2018-11-886457

Published: 2019

Journal Articles

Chemotherapy-free induction in MCL: ready for prime time?

Kami Maddocks

Blood (2018) 132 (19): 2001–2002.

https://doi.org/10.1182/blood-2018-09-875203

Published: 2018

Journal Articles

Update on mantle cell lymphoma

Kami Maddocks

Blood (2018) 132 (16): 1647–1656.

https://doi.org/10.1182/blood-2018-03-791392

Published: 2018

Journal Articles

Postibrutinib outcomes in patients with mantle cell lymphoma

Blood (2016) 127 (12): 1559–1563.

https://doi.org/10.1182/blood-2015-10-673145

Published: 2016

Journal Articles

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Blood (2016) 127 (9): 1117–1127.

https://doi.org/10.1182/blood-2015-11-679134

Published: 2016

Includes: Supplemental data

Journal Articles

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Ta-Ming Liu, Jennifer A. Woyach, Yiming Zhong, Arletta Lozanski, Gerard Lozanski, Shuai Dong, Ethan Strattan, Amy Lehman, Xiaoli Zhang, Jeffrey A. Jones, Joseph Flynn, Leslie A. Andritsos, Kami Maddocks, Samantha M. Jaglowski, Kristie A. Blum, John C. Byrd, Jason A. Dubovsky, Amy J. Johnson

Blood (2015) 126 (1): 61–68.

https://doi.org/10.1182/blood-2015-02-626846

Published: 2015

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Uncovering practice gaps in the management of mantle cell and diffuse large B-cell lymphomas amidst advances with Bruton's tyrosine kinase inhibitors

Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis

Real-world treatment patterns, patient characteristics, and outcomes of cbtki-based therapies amongst a contemporary cohort of patients with R/R MCL in the United States

Demystifying changes with upfront therapy in Mantle Cell Lymphoma: Global clinician preparedness in the aftermath of educational interventions

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease

Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder

Phase IB/II trial of epcoritamab plus ibrutinib in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

BTKi is better: a lesson learned?

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

Building on BTK inhibition in MCL

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Chemotherapy-free induction in MCL: ready for prime time?

Update on mantle cell lymphoma

Postibrutinib outcomes in patients with mantle cell lymphoma

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only